Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review

Featuring perspectives from Prof Michael Dickinson and Dr Laurie H Sehn, including the following topics:

• Introduction (0:00)
• Future Treatment of Non-Hodgkin Lymphoma (NHL) (2:24)
• Case: A man in his mid 60s with diffuse large B-cell lymphoma (DLBCL) and early relapse on axicabtagene ciloleucel receives glofitamab — Dr Sehn (8:10)
• Case: A man in his late 60s with Type 2 diabetes, congestive heart failure and chronic obstructive pulmonary disease receives glofitamab monotherapy after glofitamab with gemcitabine/oxaliplatin for relapsed GCB-type double-hit DLBCL — Matthew Lunning, DO (14:54)
• Practical Perspectives on the Current Role of Bispecific Antibodies in the Management of Lymphoma — Prof Dickinson (18:00)
• Case: A woman in her mid 50s with multiregimen-recurrent follicular lymphoma (FL) receives mosunetuzumab — Carla Casulo, MD (35:33)
• Case: A man in his late 70s with multiregimen-refractory FL receives mosunetuzumab with an ongoing complete response — Dr Sehn (40:05)
• FL and Other NHL Subtypes — Dr Sehn (45:30)

CME information and select publications